Digoxin therapy may reduce the risk for new-onset or worsening heart failure in patients with symptomatic rheumatic heart disease.

Digoxin, a cardiac glycoside derived from the foxglove plant, has been a mainstay of treatment in systolic heart failure and in rate control for atrial fibrillation. By inhibiting the cardiac ...

BUFFALO, N.Y. – University at Buffalo researchers have identified for the first time an enzyme in the foxglove plant that is responsible for the production of compounds needed to make the heart ...

Oct. 30, 2002 — Digoxin may pose a risk of death for women with heart failure, according to a retrospective analysis published in the Oct. 31 issue of the New England Journal of Medicine. Yet ...

MADRID -- Digitoxin added to guideline-directed medical therapy improved outcomes among patients with heart failure and reduced ejection fraction (HFrEF), the DIGIT-HF trial showed. The cardiac ...

Findings from the current study demonstrate that over half of chronic HF patients in the DIG trial had severe and more advanced disease as evidenced by the presence of NYHA III–IV symptoms, LVEF <25%, ...

University at Buffalo researchers have identified for the first time an enzyme in the foxglove plant that is responsible for the production of compounds needed to make the heart failure drug digoxin.

Heart drugs called digitalis glycosides, which include digoxin and digitoxin, have been used for centuries, but their place in the modern treatment of heart failure remains undefined. Results were ...

KAIMRC researchers have shown that a drug, commonly used to treat various types of heart failure, appears to increase mortality risk in certain groups of patients when it is used in place of current ...